Table 2.
Change from baseline to 12 weeks in tadalafil monotherapy (TAD+PLA-Group) and tadalafil plus tamsulosin (TAD+TAM-Group) groups.
| Variables Assesed | TAD + TAM Group n = 50 |
TAD + PLA Group n = 25 |
p Value (Anova Analysis) |
|---|---|---|---|
| IPSS 12 week (Mean ± SD) | 11.5 ± 5.4 | 11.8 ± 6.3 | |
| Delta3 M (baseline - 12wks) | −7 | −5.2 | |
| p value (paired samples T-test) | <0.001 | <0.001 | 0.084 |
| IPSS voiding 12 week (Mean ± SD) | 5.1 ± 2.7 | 8 ± 4.7 | |
| Delta3 M (baseline - 12wks) | −3.5 | −2 | |
| p value (paired samples T-test) | <0.001 | 0.074 | 0.006 |
| IPSS storage 12 week (Mean ± SD) | 5.3 ± 2.7 | 3.8 ± 3.4 | |
| Delta3 M (baseline - 12wks) | −3 | −3.1 | |
| p value (paired samples T-test) | <0.001 | <0.001 | 0.08 |
| IPSS QoL 12 week (Mean ± SD) | 2.1 ± 1 | 2.1 ± 1.7 | |
| Delta3 M (baseline - 12wks) | −1.8 | −1.3 | |
| p value (paired samples T-test) | <0.001 | 0.009 | 0.321 |
| IIEF-5 12 week (Mean ± SD) | 17.7 ± 3.3 | 19.9 ± 5.1 | |
| Delta3 M (baseline - 12wks) | 5.7 | 6.1 | |
| p value (paired samples T-test) | <0.001 | <0.001 | 0.255 |
| Q max 12 week (Mean ± SD) | 14.5 ± 3.7 | 11.8 ± 4 | |
| Delta3 M (baseline - 12wks) | 4.2 | 2.2 | |
| p value (paired samples T-test) | <0.001 | <0.001 | 0.027 |
p value: significance of the analysis of variance (ANOVA). SD = standard deviation; IPSS = International Prostate Symptom Score; IIEF-5 = International Index of Erectile Function-5; Qmax = maximum urinary flow rate.